Loading…
← CockpitCompetitor Analysis › ISRG Intuitive SurgicalOpen in the cockpit ↗

Intuitive SurgicalISRGCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Makes the da Vinci surgical robots that let surgeons perform minimally invasive operations with robotic instruments.

Momentum strong 64
Mkt cap
$146B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$1.13B
20-day average traded
Fwd P/E
34.8×
forward earnings
ROIC−WACC
+11.9 pp
WACC 12.3%
Hurdle
+11 pp
Req g minus delivered
Next earnings
69 days
26 Jan 2027
Close · USD$420.95
1D-2.2%
1W-6.4%
1M-3.9%
3M+12.4%
6M-6.2%
YTD-25.7%
1Y-23.0%
ATR %3.4%
Beta0.95
52w lowhigh30.3% off high

What Intuitive Surgical does

Makes the da Vinci surgical robots that let surgeons perform minimally invasive operations with robotic instruments.

Hospitals buy or lease the robot, then pay for instruments used in each operation and for service contracts, so revenue grows with the number of procedures performed rather than only with robot sales. Most revenue now recurs. The first system gained US approval in 2000.

Products and services

  • da Vinci surgical systems
  • Instruments & accessories (recurring revenue)
  • Ion robotic bronchoscopy

Customers

  • hospitals
  • surgeons (trained on the platform)

Where it sits in the supply chain

  • Medical devices
  • Surgical robotics
  • Robotic systems + reusable instruments…

What could go right

  • Growing global adoption of robotic surgery
  • Recurring instrument/service revenue growth

What could go wrong

  • New robotic-surgery competitors entering market
  • Hospital capital-spending cycles

Moat: wide (installed base, switching costs, IP / patents). Surgeon training, hospital capital investment and instrument recurring revenue lock in the installed base.

Headquarters: Sunnyvale, California, US · Founded: 1995 · Employees: 17,021

Named competitors

Intuitive Surgical at a glance

Size Intuitive Surgical (ISRG) is a United States Health Care company (Medical Specialties) with a market value of $146B, the 81st largest of 3,085 United States companies the cockpit tracks. Shares closed at $420.95 on 18 Nov 2026.

Performance Over six months the shares fell 6.2%, against +26.6% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 18 in its peer set.

Growth Revenue grew 20.4% over the last twelve months (peer median +8.6%); the operating margin is 32.2% (peer median 19.1%).

Valuation It trades at 34.8× forward earnings against a peer median of 24.8× (2nd most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 30% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 11.9 points above its cost of capital (12.3% WACC).

Short interest Short interest is 2.0% of the free float (30 Oct 2026).

Next results Next results expected around 26 Jan 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 126ISRG 96
Six months, rebased to 100: Intuitive Surgical against the median of its 17 peers (local-currency closes).

Intuitive Surgical financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$11.6B$10.1B$8.35B$7.12B$6.22B
Revenue growth—+21%+17%+14%—
Gross profit$7.78B$6.64B$5.63B$4.73B$4.19B
EBITDA$4.51B$3.57B$2.80B$2.20B$1.96B
Net income$2.96B$2.86B$2.32B$1.80B$1.32B
Free cash flow$3.60B$2.49B$1.30B$750M$958M
Capital expenditure$492M$540M$1.11B$1.06B$532M
Total debt$0$171M$146M$89.8M$93.8M

Quarterly statements and history in the cockpit →

Intuitive Surgical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%-10%0%+10%+20%DHRMDTSYKABTELTMOBSXEWBDXIDXXMDLNA7741GEHCALCISRG6-month return →1-month return →
Up and to the right = strong over both horizons. Intuitive Surgical is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×30×40×DHRMDTSYKABTELBSXEWBDXIDXXAWATISRGRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Intuitive Surgical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%DHRMDTSYKABTELBSXEWBDXIDXXSHLAWATGEHCISRGGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Intuitive Surgical is the large dot.

Intuitive Surgical competitors and peer comparison

Head to head with its named competitors (ISRG vs MDT vs SYK vs JNJ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Intuitive Surgical ISRG$146B-6%+20%32%34.8×29.6%
Medtronic MDT$129B+30%+10%20%16.8×9.1%
Stryker SYK$121B-1%+8%25%19.9×10.7%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%

How Intuitive Surgical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Intuitive Surgical against its 17 peers (data as of 18 Nov 2026)
MeasureISRGPeer medianRank in peer set
1-month return-3.9%+5.8%3rd lowest of 18
6-month return-6.2%+26.6%3rd lowest of 18
Distance from 52-week high-30.3%-7.2%3rd lowest of 18
Revenue growth (TTM)+20.4%+8.6%2nd highest of 18
Operating margin32.2%19.1%2nd highest of 18
Forward P/E34.8×24.8×2nd most expensive of 18
Growth the price implies (Req g, 7 yrs)29.6%15.9%2nd most demanding of 18
Growth delivered (Del g)+18.2%+6.1%highest of 18
Hurdle (Req g minus delivered)+11.4 pp+6.0 pp7th most demanding of 18
ROIC minus cost of capital+11.9 pp+0.8 pp4th highest of 18
EV / EBITDA31.5×19.1×3rd most expensive of 18
Net debt / EBITDA-0.9×2.0×3rd least indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Intuitive Surgical ISRGUnited States$146B-6%+20%32%34.8×29.6%+18.2%
Danaher DHRUnited States$161B+34%+6%21%25.1×20.8%+2.0%
Medtronic MDTUnited States$129B+30%+10%20%16.8×9.1%+3.8%
Stryker SYKUnited States$121B-1%+8%25%19.9×10.7%+11.8%
Abbott Laboratories ABTUnited States$181B+18%+10%14%17.9×16.5%+5.1%
EssilorLuxottica EL.PAFrance$91.9B+5%+8%12%24.8×18.4%+14.6%
Thermo Fisher Scientific TMOUnited States$257B+53%+8%19%25.7×21.3%+6.7%
Boston Scientific BSXUnited States$63.3B-23%+9%21%14.1×5.8%+15.2%
Edwards Lifesciences EWUnited States$60.5B+27%+13%29%32.3×17.1%+6.7%
Becton Dickinson BDXUnited States$58.9B+48%-7%16%16.3×-1.6%+0.3%
Idexx Laboratories IDXXUnited States$55.0B+26%+12%32%42.9×29.0%+9.7%
Siemens Healthineers SHL.DEGermany$53.7B+27%+1%14%18.9×9.6%+5.6%
Medline MDLNUnited States$51.5B+8%+12%6%25.6×15.9%+9.9%
Agilent Technologies AUnited States$50.0B+56%+9%24%27.0×23.3%+5.4%
Hoya 7741.TJapan$49.0B-16%+13%32%27.7×14.1%+11.6%
Waters WATUnited States$45.8B+37%+81%10%29.1×48.1%+6.0%
GE HealthCare GEHCUnited States$37.8B+30%+7%14%15.6×5.0%+3.7%
Alcon ALC.SWSwitzerland$36.9B+18%+1%12%21.5×12.2%+6.1%

Questions

Who are Intuitive Surgical's main competitors?
Named competitors: Medtronic (Hugo) (MDT), Stryker (SYK), Johnson & Johnson (Ottava) (JNJ), CMR Surgical (Versius) (private or unlisted). The cockpit's measured peer set (industry) also includes Danaher (DHR), Medtronic (MDT), Stryker (SYK), Abbott Laboratories (ABT), EssilorLuxottica (EL.PA), Thermo Fisher Scientific (TMO).
Is Intuitive Surgical expensive compared with its peers?
On forward p/e it trades at 34.8× against a peer median of 24.8×, 2nd most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 30% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Intuitive Surgical stock performed?
Over six months to 18 Nov 2026 the shares returned -6.2% against +26.6% for the median peer; over one year -23.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.